全体要約
糖尿病性神経障害治療薬市場は、2022年の売上高を基に、2023年から2029年にかけての予測を地域別および市場セクター別に分析しています。アメリカ、中国、ヨーロッパの市場はそれぞれ成長が見込まれ、主要企業にはアストラゼネカ、ジョンソン・エンド・ジョンソン、武田薬品などが含まれます。これらの企業は、2022年において市場の大部分を占めています。
このレポートは、糖尿病性神経障害治療薬の製品タイプやアプリケーション、地域別の市場シェアを詳細に示しています。市場はカプセル、錠剤、その他のタイプに分かれ、対称性神経障害や焦点性・多焦点性神経障害に応じたアプリケーションが存在します。
関連する質問
AstraZeneca, Johnson & Johnson, Takeda, Mitsubishi Chemical, Avanir Pharmaceuticals, Dong-A Pharmaceutical Co., Ltd., Immune Pharmaceuticals, MediciNova, Sangamo BioSciences
製品セグメンテーションの重要なトレンド, 主要企業の戦略分析, 地域別市場の成長機会
概要
LPI (LP Information)の最新の研究報告書「糖尿病神経障害治療薬産業予測」では、過去の販売状況を調査し、2022年の世界の糖尿病神経障害治療薬の販売総額をレビューしています。2023年から2029年までの予測される糖尿病神経障害治療薬の販売について、地域や市場セクター別に包括的な分析を提供します。この報告書では、地域、市場セクター、サブセクター別に分けられた糖尿病神経障害治療薬の販売データが示されており、世界の糖尿病神経障害治療薬産業に関する詳細な分析がUS$百万単位で提供されています。
このインサイトレポートは、世界的な糖尿病神経障害治療薬の状況について包括的な分析を提供し、製品セグメンテーション、企業形成、収益、市場シェア、最新の開発、M&A活動に関連する重要なトレンドを強調しています。また、このレポートは、糖尿病神経障害治療薬のポートフォリオと能力、市場参入戦略、市場ポジション、および地理的フットプリントに焦点を当てて、主要なグローバル企業の戦略も分析し、加速するグローバルな糖尿病神経障害治療薬市場におけるこれらの企業のユニークなポジションをよりよく理解するためのものです。
このインサイトレポートは、糖尿病神経障害治療薬のグローバルな展望を形成する主な市場動向、推進要因、および影響要因を評価し、タイプ、アプリケーション、地域、市場規模別に予測を分解して、新たな機会のポケットを強調しています。数百のボトムアップの質的および量的市場データに基づく透明な方法論を用いたこの研究予測は、糖尿病神経障害治療薬の現状と将来の軌道に関する非常に繊細な視点を提供します。
世界の糖尿病神経障害治療薬市場の規模は、2022年から2029年にかけてXX米ドルからXX米ドルに成長すると予測されています。2023年から2029年にかけて、年平均成長率（CAGR）がXX%と期待されています。
アメリカ合衆国の糖尿病神経障害治療薬市場は、2022年のXX米ドルから2029年までにXX米ドルに増加すると推定されており、2023年から2029年までの間にXX%の年平均成長率で成長すると予測されています。
中国の糖尿病神経障害治療薬市場は、2022年のXX米ドルから2029年にはXX米ドルに増加すると見込まれています。2023年から2029年までの間にCAGRはXX%です。
欧州の糖尿病神経障害治療薬市場は、2022年のXX米ドルから2029年のXX米ドルに増加すると推定されており、2023年から2029年までのCAGRはXX%です。
グローバルな主要な糖尿病神経障害治療薬のプレーヤーは、アストラゼネカ、ジョンソン・エンド・ジョンソン、武田薬品、三菱ケミカル、アバニア・ファーマシューティカルズ、東亜製薬株式会社、イミューン・ファーマシューティカルズ、メディシノバ、サンガモ・バイオサイエンシズなどです。収益の点では、世界の2つの最大の企業が2022年にほぼXX%のシェアを占めました。
このレポートは、糖尿病神経障害治療薬市場の製品タイプ、アプリケーション、主要プレーヤー、主要地域および国による包括的な概要、市場シェア、および成長機会を示しています。
市場セグメンテーション
種類別セグメンテーション
カプセル
ピル
他の
アプリケーションによるセグメンテーション
対称性神経障害
焦点性および多焦点神経障害
この報告書は市場を地域別に分割しています。
アメリカ大陸
アメリカ合衆国
カナダ
メキシコ
ブラジル
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下のプロファイルされた企業は、主要な専門家からの情報収集および企業のカバレッジ、製品ポートフォリオ、市場浸透率の分析に基づいて選定されています。
アストラゼネカ
ジョンソン・エンド・ジョンソン
武田
三菱ケミカル
アバニールファーマシューティカルズ
ドンア製薬株式会社
免疫製薬
メディシノバ
サンガモ・バイオサイエンシズ
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 調査範囲
1.1 市場イントロダクション
1.2 対象年
1.3 調査目的
1.4 市場調査手法
1.5 調査プロセスとデータソース
1.6 経済指標
1.7 通貨
1.8 市場予測における留意事項
2 エグゼクティブサマリー
2.1 世界市場概要
2.1.1 グローバルの糖尿病性神経障害治療薬市場規模、（2018年～2029年）
2.1.2 糖尿病性神経障害治療薬市場規模、CAGR（地域別）（2018年 vs 2022年 vs 2029年）
2.2 糖尿病性神経障害治療薬セグメント、タイプ別
2.2.1 カプセル
2.2.2 ピル
2.2.3 その他
2.3 糖尿病性神経障害治療薬市場規模：タイプ別
2.3.1 糖尿病性神経障害治療薬市場規模、CAGR（タイプ別）（2018年 vs 2022年 vs 2029年）
2.3.2 グローバルの糖尿病性神経障害治療薬市場規模、市場シェア（タイプ別）（2018年～2023年）
2.4 糖尿病性神経障害治療薬セグメント、用途別
2.4.1 対称性神経障害
2.4.2 局所性神経障害と多巣性神経障害
2.5 糖尿病性神経障害治療薬市場規模：用途別
2.5.1 糖尿病性神経障害治療薬市場規模、CAGR（用途別）（2018年 vs 2022年 vs 2029年）
2.5.2 グローバルの糖尿病性神経障害治療薬市場規模、市場シェア（用途別）（2018年～2023年）
3 糖尿病性神経障害治療薬市場規模：プレイヤー別
3.1 糖尿病性神経障害治療薬市場規模、市場シェア（プレイヤー別）
3.1.1 グローバルにおける糖尿病性神経障害治療薬市場の収益規模、プレイヤー別（2018年～2023年）
3.1.2 グローバルにおける糖尿病性神経障害治療薬市場の収益シェア、プレイヤー別（2018年～2023年）
3.2 グローバルの糖尿病性神経障害治療薬市場キープレイヤー拠点および提供製品
3.3 市場集中度分析
3.3.1 競合情勢分析
3.3.2 集中度レシオ（CR3、CR5、CR10）（2021年～2023年）
3.4 新製品・潜在的参入
3.5 M&A、拡大
4 糖尿病性神経障害治療薬、地域別
4.1 糖尿病性神経障害治療薬市場規模（地域別）（2018年～2023年）
4.2 アメリカズにおける糖尿病性神経障害治療薬市場規模成長（2018年〜2023年）
4.3 APACにおける糖尿病性神経障害治療薬市場規模成長（2018年〜2023年）
4.4 ヨーロッパにおける糖尿病性神経障害治療薬市場規模成長（2018年〜2023年）
4.5 中東・アフリカにおける糖尿病性神経障害治療薬市場規模成長（2018年〜2023年）
5 アメリカズ
5.1 アメリカズにおける糖尿病性神経障害治療薬市場規模、国別（2018年〜2023年）
5.2 アメリカズにおける糖尿病性神経障害治療薬市場規模、タイプ別（2018年〜2023年）
5.3 アメリカズにおける糖尿病性神経障害治療薬市場規模、用途別（2018年〜2023年）
5.4 米国
5.5 カナダ
5.6 メキシコ
5.7 ブラジル
6 APAC
6.1 APACにおける糖尿病性神経障害治療薬市場規模、地域別（2018年〜2023年）
6.2 APACにおける糖尿病性神経障害治療薬市場規模、タイプ別（2018年〜2023年）
6.3 APACにおける糖尿病性神経障害治療薬市場規模、用途別（2018年〜2023年）
6.4 中国
6.5 日本
6.6 韓国
6.7 東南アジア
6.8 インド
6.9 オーストラリア
7 ヨーロッパ
7.1 ヨーロッパの糖尿病性神経障害治療薬 国別（2018年～2023年）
7.2 ヨーロッパにおける糖尿病性神経障害治療薬市場規模、タイプ別（2018年〜2023年）
7.3 ヨーロッパにおける糖尿病性神経障害治療薬市場規模、用途別（2018年〜2023年）
7.4 ドイツ
7.5 フランス
7.6 英国
7.7 イタリア
7.8 ロシア
8 中東・アフリカ
8.1 中東・アフリカの糖尿病性神経障害治療薬 地域別（2018年～2023年）
8.2 中東・アフリカにおける糖尿病性神経障害治療薬市場規模、タイプ別（2018年〜2023年）
8.3 中東・アフリカにおける糖尿病性神経障害治療薬市場規模、用途別（2018年〜2023年）
8.4 エジプト
8.5 南アフリカ
8.6 イスラエル
8.7 トルコ
8.8 GCC地域
9 市場ドライバー・課題・トレンド
9.1 市場ドライバー・成長機会
9.2 市場課題・リスク
9.3 業界トレンド
10 グローバルの糖尿病性神経障害治療薬市場、市場予測
10.1 グローバルの糖尿病性神経障害治療薬、市場予測（地域別）（2024年～2029年）
10.1.1 グローバルの糖尿病性神経障害治療薬、市場予測（地域別）（2024年～2029年）
10.1.2 アメリカズの糖尿病性神経障害治療薬、市場予測
10.1.3 APACの糖尿病性神経障害治療薬、市場予測
10.1.4 ヨーロッパの糖尿病性神経障害治療薬、市場予測
10.1.5 中東・アフリカの糖尿病性神経障害治療薬、市場予測
10.2 アメリカズの糖尿病性神経障害治療薬、市場予測（国別）（2024年～2029年）
10.3 APACの糖尿病性神経障害治療薬、市場予測（地域別）（2024年～2029年）
10.4 ヨーロッパの糖尿病性神経障害治療薬、市場予測（国別）（2024年～2029年）
10.5 中東・アフリカの糖尿病性神経障害治療薬、市場予測（地域別）（2024年～2029年）
10.6 グローバルの糖尿病性神経障害治療薬、市場予測（タイプ別）（2024年～2029年）
10.7 グローバルの糖尿病性神経障害治療薬、市場予測（用途別）（2024年～2029年）
11 キープレイヤー分析
11.1 AstraZeneca
11.1.1 AstraZeneca：企業情報
11.1.2 AstraZeneca：糖尿病性神経障害治療薬分野の提供製品
11.1.3 AstraZeneca：糖尿病性神経障害治療薬収益・グロスマージンおよび市場シェア（2018年～2023年）
11.1.4 AstraZeneca：主要事業概要
11.1.5 AstraZeneca：直近の展開
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson：企業情報
11.2.2 Johnson & Johnson：糖尿病性神経障害治療薬分野の提供製品
11.2.3 Johnson & Johnson：糖尿病性神経障害治療薬収益・グロスマージンおよび市場シェア（2018年～2023年）
11.2.4 Johnson & Johnson：主要事業概要
11.2.5 Johnson & Johnson：直近の展開
11.3 Takeda
11.3.1 Takeda：企業情報
11.3.2 Takeda：糖尿病性神経障害治療薬分野の提供製品
11.3.3 Takeda：糖尿病性神経障害治療薬収益・グロスマージンおよび市場シェア（2018年～2023年）
11.3.4 Takeda：主要事業概要
11.3.5 Takeda：直近の展開
11.4 Mitsubishi Chemical
11.4.1 Mitsubishi Chemical：企業情報
11.4.2 Mitsubishi Chemical：糖尿病性神経障害治療薬分野の提供製品
11.4.3 Mitsubishi Chemical：糖尿病性神経障害治療薬収益・グロスマージンおよび市場シェア（2018年～2023年）
11.4.4 Mitsubishi Chemical：主要事業概要
11.4.5 Mitsubishi Chemical：直近の展開
11.5 Avanir Pharmaceuticals
11.5.1 Avanir Pharmaceuticals：企業情報
11.5.2 Avanir Pharmaceuticals：糖尿病性神経障害治療薬分野の提供製品
11.5.3 Avanir Pharmaceuticals：糖尿病性神経障害治療薬収益・グロスマージンおよび市場シェア（2018年～2023年）
11.5.4 Avanir Pharmaceuticals：主要事業概要
11.5.5 Avanir Pharmaceuticals：直近の展開
11.6 Dong-A Pharmaceutical Co\., Ltd
11.7 Immune Pharmaceuticals
11.7.1 Immune Pharmaceuticals：企業情報
11.7.2 Immune Pharmaceuticals：糖尿病性神経障害治療薬分野の提供製品
11.7.3 Immune Pharmaceuticals：糖尿病性神経障害治療薬収益・グロスマージンおよび市場シェア（2018年～2023年）
11.7.4 Immune Pharmaceuticals：主要事業概要
11.7.5 Immune Pharmaceuticals：直近の展開
11.8 MediciNova
11.8.1 MediciNova：企業情報
11.8.2 MediciNova：糖尿病性神経障害治療薬分野の提供製品
11.8.3 MediciNova：糖尿病性神経障害治療薬収益・グロスマージンおよび市場シェア（2018年～2023年）
11.8.4 MediciNova：主要事業概要
11.8.5 MediciNova：直近の展開
11.9 Sangamo BioSciences
11.9.1 Sangamo BioSciences：企業情報
11.9.2 Sangamo BioSciences：糖尿病性神経障害治療薬分野の提供製品
11.9.3 Sangamo BioSciences：糖尿病性神経障害治療薬収益・グロスマージンおよび市場シェア（2018年～2023年）
11.9.4 Sangamo BioSciences：主要事業概要
11.9.5 Sangamo BioSciences：直近の展開
12 調査の結果・結論
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
LPI (LP Information)' newest research report, the “Diabetic Neurological Disorder Therapeutic Drug Industry Forecast” looks at past sales and reviews total world Diabetic Neurological Disorder Therapeutic Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Diabetic Neurological Disorder Therapeutic Drug sales for 2023 through 2029. With Diabetic Neurological Disorder Therapeutic Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Diabetic Neurological Disorder Therapeutic Drug industry.
This Insight Report provides a comprehensive analysis of the global Diabetic Neurological Disorder Therapeutic Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Diabetic Neurological Disorder Therapeutic Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Diabetic Neurological Disorder Therapeutic Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Diabetic Neurological Disorder Therapeutic Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Diabetic Neurological Disorder Therapeutic Drug.
The global Diabetic Neurological Disorder Therapeutic Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Diabetic Neurological Disorder Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Diabetic Neurological Disorder Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Diabetic Neurological Disorder Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Diabetic Neurological Disorder Therapeutic Drug players cover AstraZeneca, Johnson & Johnson, Takeda, Mitsubishi Chemical, Avanir Pharmaceuticals, Dong-A Pharmaceutical Co., Ltd., Immune Pharmaceuticals, MediciNova and Sangamo BioSciences, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Diabetic Neurological Disorder Therapeutic Drug market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Capsule
Pills
Other
Segmentation by application
Symmetrical Neuropathy
Focal and Multifocal Neuropathy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Johnson & Johnson
Takeda
Mitsubishi Chemical
Avanir Pharmaceuticals
Dong-A Pharmaceutical Co., Ltd.
Immune Pharmaceuticals
MediciNova
Sangamo BioSciences
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Diabetic Neurological Disorder Therapeutic Drug Market Size 2018-2029
2.1.2 Diabetic Neurological Disorder Therapeutic Drug Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Diabetic Neurological Disorder Therapeutic Drug Segment by Type
2.2.1 Capsule
2.2.2 Pills
2.2.3 Other
2.3 Diabetic Neurological Disorder Therapeutic Drug Market Size by Type
2.3.1 Diabetic Neurological Disorder Therapeutic Drug Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Type (2018-2023)
2.4 Diabetic Neurological Disorder Therapeutic Drug Segment by Application
2.4.1 Symmetrical Neuropathy
2.4.2 Focal and Multifocal Neuropathy
2.5 Diabetic Neurological Disorder Therapeutic Drug Market Size by Application
2.5.1 Diabetic Neurological Disorder Therapeutic Drug Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Application (2018-2023)
3 Diabetic Neurological Disorder Therapeutic Drug Market Size by Player
3.1 Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Players
3.1.1 Global Diabetic Neurological Disorder Therapeutic Drug Revenue by Players (2018-2023)
3.1.2 Global Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Players (2018-2023)
3.2 Global Diabetic Neurological Disorder Therapeutic Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Diabetic Neurological Disorder Therapeutic Drug by Regions
4.1 Diabetic Neurological Disorder Therapeutic Drug Market Size by Regions (2018-2023)
4.2 Americas Diabetic Neurological Disorder Therapeutic Drug Market Size Growth (2018-2023)
4.3 APAC Diabetic Neurological Disorder Therapeutic Drug Market Size Growth (2018-2023)
4.4 Europe Diabetic Neurological Disorder Therapeutic Drug Market Size Growth (2018-2023)
4.5 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size Growth (2018-2023)
5 Americas
5.1 Americas Diabetic Neurological Disorder Therapeutic Drug Market Size by Country (2018-2023)
5.2 Americas Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2018-2023)
5.3 Americas Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Diabetic Neurological Disorder Therapeutic Drug Market Size by Region (2018-2023)
6.2 APAC Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2018-2023)
6.3 APAC Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Diabetic Neurological Disorder Therapeutic Drug by Country (2018-2023)
7.2 Europe Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2018-2023)
7.3 Europe Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug by Region (2018-2023)
8.2 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2018-2023)
8.3 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.1 Global Diabetic Neurological Disorder Therapeutic Drug Forecast by Regions (2024-2029)
10.1.1 Global Diabetic Neurological Disorder Therapeutic Drug Forecast by Regions (2024-2029)
10.1.2 Americas Diabetic Neurological Disorder Therapeutic Drug Forecast
10.1.3 APAC Diabetic Neurological Disorder Therapeutic Drug Forecast
10.1.4 Europe Diabetic Neurological Disorder Therapeutic Drug Forecast
10.1.5 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Forecast
10.2 Americas Diabetic Neurological Disorder Therapeutic Drug Forecast by Country (2024-2029)
10.2.1 United States Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.2.2 Canada Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.2.3 Mexico Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.2.4 Brazil Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.3 APAC Diabetic Neurological Disorder Therapeutic Drug Forecast by Region (2024-2029)
10.3.1 China Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.3.2 Japan Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.3.3 Korea Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.3.4 Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.3.5 India Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.3.6 Australia Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.4 Europe Diabetic Neurological Disorder Therapeutic Drug Forecast by Country (2024-2029)
10.4.1 Germany Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.4.2 France Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.4.3 UK Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.4.4 Italy Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.4.5 Russia Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.5 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Forecast by Region (2024-2029)
10.5.1 Egypt Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.5.2 South Africa Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.5.3 Israel Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.5.4 Turkey Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.5.5 GCC Countries Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.6 Global Diabetic Neurological Disorder Therapeutic Drug Forecast by Type (2024-2029)
10.7 Global Diabetic Neurological Disorder Therapeutic Drug Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 AstraZeneca
11.1.1 AstraZeneca Company Information
11.1.2 AstraZeneca Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.1.3 AstraZeneca Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 AstraZeneca Main Business Overview
11.1.5 AstraZeneca Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.2.3 Johnson & Johnson Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Takeda
11.3.1 Takeda Company Information
11.3.2 Takeda Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.3.3 Takeda Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Takeda Main Business Overview
11.3.5 Takeda Latest Developments
11.4 Mitsubishi Chemical
11.4.1 Mitsubishi Chemical Company Information
11.4.2 Mitsubishi Chemical Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.4.3 Mitsubishi Chemical Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Mitsubishi Chemical Main Business Overview
11.4.5 Mitsubishi Chemical Latest Developments
11.5 Avanir Pharmaceuticals
11.5.1 Avanir Pharmaceuticals Company Information
11.5.2 Avanir Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.5.3 Avanir Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Avanir Pharmaceuticals Main Business Overview
11.5.5 Avanir Pharmaceuticals Latest Developments
11.6 Dong-A Pharmaceutical Co., Ltd.
11.6.1 Dong-A Pharmaceutical Co., Ltd. Company Information
11.6.2 Dong-A Pharmaceutical Co., Ltd. Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.6.3 Dong-A Pharmaceutical Co., Ltd. Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Dong-A Pharmaceutical Co., Ltd. Main Business Overview
11.6.5 Dong-A Pharmaceutical Co., Ltd. Latest Developments
11.7 Immune Pharmaceuticals
11.7.1 Immune Pharmaceuticals Company Information
11.7.2 Immune Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.7.3 Immune Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Immune Pharmaceuticals Main Business Overview
11.7.5 Immune Pharmaceuticals Latest Developments
11.8 MediciNova
11.8.1 MediciNova Company Information
11.8.2 MediciNova Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.8.3 MediciNova Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 MediciNova Main Business Overview
11.8.5 MediciNova Latest Developments
11.9 Sangamo BioSciences
11.9.1 Sangamo BioSciences Company Information
11.9.2 Sangamo BioSciences Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.9.3 Sangamo BioSciences Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Sangamo BioSciences Main Business Overview
11.9.5 Sangamo BioSciences Latest Developments
12 Research Findings and Conclusion
List of Tables Table 1. Diabetic Neurological Disorder Therapeutic Drug Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions) Table 2. Major Players of Capsule Table 3. Major Players of Pills Table 4. Major Players of Other Table 5. Diabetic Neurological Disorder Therapeutic Drug Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions) Table 6. Global Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2018-2023) & ($ Millions) Table 7. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Type (2018-2023) Table 8. Diabetic Neurological Disorder Therapeutic Drug Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions) Table 9. Global Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2018-2023) & ($ Millions) Table 10. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Application (2018-2023) Table 11. Global Diabetic Neurological Disorder Therapeutic Drug Revenue by Players (2018-2023) & ($ Millions) Table 12. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Player (2018-2023) Table 13. Diabetic Neurological Disorder Therapeutic Drug Key Players Head office and Products Offered Table 14. Diabetic Neurological Disorder Therapeutic Drug Concentration Ratio (CR3, CR5 and CR10) & (2021-2023) Table 15. New Products and Potential Entrants Table 16. Mergers & Acquisitions, Expansion Table 17. Global Diabetic Neurological Disorder Therapeutic Drug Market Size by Regions 2018-2023 & ($ Millions) Table 18. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Regions (2018-2023) Table 19. Global Diabetic Neurological Disorder Therapeutic Drug Revenue by Country/Region (2018-2023) & ($ millions) Table 20. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Country/Region (2018-2023) Table 21. Americas Diabetic Neurological Disorder Therapeutic Drug Market Size by Country (2018-2023) & ($ Millions) Table 22. Americas Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Country (2018-2023) Table 23. Americas Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2018-2023) & ($ Millions) Table 24. Americas Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Type (2018-2023) Table 25. Americas Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2018-2023) & ($ Millions) Table 26. Americas Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Application (2018-2023) Table 27. APAC Diabetic Neurological Disorder Therapeutic Drug Market Size by Region (2018-2023) & ($ Millions) Table 28. APAC Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Region (2018-2023) Table 29. APAC Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2018-2023) & ($ Millions) Table 30. APAC Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Type (2018-2023) Table 31. APAC Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2018-2023) & ($ Millions) Table 32. APAC Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Application (2018-2023) Table 33. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size by Country (2018-2023) & ($ Millions) Table 34. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Country (2018-2023) Table 35. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2018-2023) & ($ Millions) Table 36. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Type (2018-2023) Table 37. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2018-2023) & ($ Millions) Table 38. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Application (2018-2023) Table 39. Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size by Region (2018-2023) & ($ Millions) Table 40. Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Region (2018-2023) Table 41. Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2018-2023) & ($ Millions) Table 42. Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Type (2018-2023) Table 43. Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2018-2023) & ($ Millions) Table 44. Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Application (2018-2023) Table 45. Key Market Drivers & Growth Opportunities of Diabetic Neurological Disorder Therapeutic Drug Table 46. Key Market Challenges & Risks of Diabetic Neurological Disorder Therapeutic Drug Table 47. Key Industry Trends of Diabetic Neurological Disorder Therapeutic Drug Table 48. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Forecast by Regions (2024-2029) & ($ Millions) Table 49. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share Forecast by Regions (2024-2029) Table 50. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Forecast by Type (2024-2029) & ($ Millions) Table 51. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Forecast by Application (2024-2029) & ($ Millions) Table 52. AstraZeneca Details, Company Type, Diabetic Neurological Disorder Therapeutic Drug Area Served and Its Competitors Table 53. AstraZeneca Diabetic Neurological Disorder Therapeutic Drug Product Offered Table 54. AstraZeneca Diabetic Neurological Disorder Therapeutic Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 55. AstraZeneca Main Business Table 56. AstraZeneca Latest Developments Table 57. Johnson & Johnson Details, Company Type, Diabetic Neurological Disorder Therapeutic Drug Area Served and Its Competitors Table 58. Johnson & Johnson Diabetic Neurological Disorder Therapeutic Drug Product Offered Table 59. Johnson & Johnson Main Business Table 60. Johnson & Johnson Diabetic Neurological Disorder Therapeutic Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 61. Johnson & Johnson Latest Developments Table 62. Takeda Details, Company Type, Diabetic Neurological Disorder Therapeutic Drug Area Served and Its Competitors Table 63. Takeda Diabetic Neurological Disorder Therapeutic Drug Product Offered Table 64. Takeda Main Business Table 65. Takeda Diabetic Neurological Disorder Therapeutic Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 66. Takeda Latest Developments Table 67. Mitsubishi Chemical Details, Company Type, Diabetic Neurological Disorder Therapeutic Drug Area Served and Its Competitors Table 68. Mitsubishi Chemical Diabetic Neurological Disorder Therapeutic Drug Product Offered Table 69. Mitsubishi Chemical Main Business Table 70. Mitsubishi Chemical Diabetic Neurological Disorder Therapeutic Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 71. Mitsubishi Chemical Latest Developments Table 72. Avanir Pharmaceuticals Details, Company Type, Diabetic Neurological Disorder Therapeutic Drug Area Served and Its Competitors Table 73. Avanir Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Product Offered Table 74. Avanir Pharmaceuticals Main Business Table 75. Avanir Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 76. Avanir Pharmaceuticals Latest Developments Table 77. Dong-A Pharmaceutical Co., Ltd. Details, Company Type, Diabetic Neurological Disorder Therapeutic Drug Area Served and Its Competitors Table 78. Dong-A Pharmaceutical Co., Ltd. Diabetic Neurological Disorder Therapeutic Drug Product Offered Table 79. Dong-A Pharmaceutical Co., Ltd. Main Business Table 80. Dong-A Pharmaceutical Co., Ltd. Diabetic Neurological Disorder Therapeutic Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 81. Dong-A Pharmaceutical Co., Ltd. Latest Developments Table 82. Immune Pharmaceuticals Details, Company Type, Diabetic Neurological Disorder Therapeutic Drug Area Served and Its Competitors Table 83. Immune Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Product Offered Table 84. Immune Pharmaceuticals Main Business Table 85. Immune Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 86. Immune Pharmaceuticals Latest Developments Table 87. MediciNova Details, Company Type, Diabetic Neurological Disorder Therapeutic Drug Area Served and Its Competitors Table 88. MediciNova Diabetic Neurological Disorder Therapeutic Drug Product Offered Table 89. MediciNova Main Business Table 90. MediciNova Diabetic Neurological Disorder Therapeutic Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 91. MediciNova Latest Developments Table 92. Sangamo BioSciences Details, Company Type, Diabetic Neurological Disorder Therapeutic Drug Area Served and Its Competitors Table 93. Sangamo BioSciences Diabetic Neurological Disorder Therapeutic Drug Product Offered Table 94. Sangamo BioSciences Main Business Table 95. Sangamo BioSciences Diabetic Neurological Disorder Therapeutic Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 96. Sangamo BioSciences Latest Developments List of Figures Figure 1. Diabetic Neurological Disorder Therapeutic Drug Report Years Considered Figure 2. Research Objectives Figure 3. Research Methodology Figure 4. Research Process and Data Source Figure 5. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Growth Rate 2018-2029 ($ Millions) Figure 6. Diabetic Neurological Disorder Therapeutic Drug Sales by Geographic Region (2018, 2022 & 2029) & ($ millions) Figure 7. Diabetic Neurological Disorder Therapeutic Drug Sales Market Share by Country/Region (2022) Figure 8. Diabetic Neurological Disorder Therapeutic Drug Sales Market Share by Country/Region (2018, 2022 & 2029) Figure 9. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Type in 2022 Figure 10. Diabetic Neurological Disorder Therapeutic Drug in Symmetrical Neuropathy Figure 11. Global Diabetic Neurological Disorder Therapeutic Drug Market: Symmetrical Neuropathy (2018-2023) & ($ Millions) Figure 12. Diabetic Neurological Disorder Therapeutic Drug in Focal and Multifocal Neuropathy Figure 13. Global Diabetic Neurological Disorder Therapeutic Drug Market: Focal and Multifocal Neuropathy (2018-2023) & ($ Millions) Figure 14. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Application in 2022 Figure 15. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Player in 2022 Figure 16. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Regions (2018-2023) Figure 17. Americas Diabetic Neurological Disorder Therapeutic Drug Market Size 2018-2023 ($ Millions) Figure 18. APAC Diabetic Neurological Disorder Therapeutic Drug Market Size 2018-2023 ($ Millions) Figure 19. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size 2018-2023 ($ Millions) Figure 20. Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size 2018-2023 ($ Millions) Figure 21. Americas Diabetic Neurological Disorder Therapeutic Drug Value Market Share by Country in 2022 Figure 22. United States Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 23. Canada Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 24. Mexico Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 25. Brazil Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 26. APAC Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Region in 2022 Figure 27. APAC Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Type in 2022 Figure 28. APAC Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Application in 2022 Figure 29. China Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 30. Japan Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 31. Korea Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 32. Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 33. India Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 34. Australia Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 35. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Country in 2022 Figure 36. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Type (2018-2023) Figure 37. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Application (2018-2023) Figure 38. Germany Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 39. France Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 40. UK Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 41. Italy Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 42. Russia Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 43. Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Region (2018-2023) Figure 44. Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Type (2018-2023) Figure 45. Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Application (2018-2023) Figure 46. Egypt Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 47. South Africa Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 48. Israel Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 49. Turkey Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 50. GCC Country Diabetic Neurological Disorder Therapeutic Drug Market Size Growth 2018-2023 ($ Millions) Figure 51. Americas Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 52. APAC Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 53. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 54. Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 55. United States Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 56. Canada Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 57. Mexico Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 58. Brazil Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 59. China Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 60. Japan Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 61. Korea Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 62. Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 63. India Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 64. Australia Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 65. Germany Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 66. France Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 67. UK Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 68. Italy Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 69. Russia Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 70. Spain Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 71. Egypt Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 72. South Africa Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 73. Israel Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 74. Turkey Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 75. GCC Countries Diabetic Neurological Disorder Therapeutic Drug Market Size 2024-2029 ($ Millions) Figure 76. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share Forecast by Type (2024-2029) Figure 77. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share Forecast by Application (2024-2029)
